Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy

References

• FriedmanDSWolfsRCO’ColmainBJPrevalence of open-angle glaucoma among adults in the United StatesArch Ophthalmol2004122453253815078671
   PubMedGoogle Scholar
• VarmaRLeePPGoldbergIKotakSAn assessment of the health and economic burdens of glaucomaAm J Ophthalmol2011152451552221961848
   PubMed Web of Science ®Google Scholar
• WeinrebRNKhawPTPrimary open-angle glaucomaLancet200436394221711172015158634
   PubMed Web of Science ®Google Scholar
• HeijlALeskeMCBengtssonBReduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma TrialArch Ophthalmol2002120101268127912365904
   PubMed Web of Science ®Google Scholar
• LeskeMCHeijlAHymanLBengtssonBKomaroffEFactors for progression and glaucoma treatment: the Early Manifest Glaucoma TrialCurr Opin Ophthalmol200415210210615021220
   PubMedGoogle Scholar
• ChauhanBCMikelbergFSBalasziAGCanadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucomaArch Ophthalmol200812681030103618695095
   PubMedGoogle Scholar
• FishmanPCohenSBar-YehudaSTargeting the A3 adenosine receptor for glaucoma treatment (review)Mol Med Rep2013761723172523563604
   PubMed Web of Science ®Google Scholar
• KaufmanMBPharmaceutical approval updatePT20184312260
   Google Scholar
• KaufmanPLLatanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertensionExpert Opin Pharmacother201718443344428234563
   PubMed Web of Science ®Google Scholar
• HoySMLatanoprostene bunod ophthalmic solution 0.024%: a review in open-angle glaucoma and ocular hypertensionDrugs201878777378029761382
   PubMed Web of Science ®Google Scholar
• LuLJTsaiJCLiuJLjLLuiJNovel pharmacologic candidates for treatment of primary open-angle glaucomaYale J Biol Med201790111111828356898
   PubMed Web of Science ®Google Scholar
• LindseyJDKashiwagiKKashiwagiFWeinrebRNProstaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitroInvest Ophthalmol Vis Sci19973811221422239344344
   PubMed Web of Science ®Google Scholar
• CavetMEVittitowJLImpagnatielloFOnginiEBastiaENitric oxide (NO): an emerging target for the treatment of glaucomaInvest Ophthalmol Vis Sci20145585005501525125670
   PubMed Web of Science ®Google Scholar
• CavetMEDecoryHHThe role of nitric oxide in the intraocular pressure lowering efficacy of latanoprostene bunod: review of nonclinical studiesJ Ocul Pharmacol Ther2018341–2526028783422
   PubMed Web of Science ®Google Scholar
• SaekiTTsurugaHAiharaMAraieMRittenhouseKDose–response profile of PF-03187207 (PF-207) and peak IOP lowering response following single topical administration to FP receptor knockout mice versus wild type miceInvest Ophthalmol Vis Sci2009504064
   Google Scholar
• AraieMSforzoliniBSVittitowJWeinrebRNEvaluation of the effect of latanoprostene bunod ophthalmic solution, 0.024% in lowering intraocular pressure over 24 h in healthy Japanese subjectsAdv Ther201532111128113926563323
   PubMed Web of Science ®Google Scholar
• EvelethDStaritaCTresslerCA 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertensionBMC Ophthalmol201212922607109
   PubMed Web of Science ®Google Scholar
• WeinrebRNOngTScassellati SforzoliniBA randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER studyBr J Ophthalmol201599673874525488946
   PubMed Web of Science ®Google Scholar
• LiuJHKSlightJRVittitowJLScassellati SforzoliniBWeinrebRNEfficacy of Latanoprostene bunod 0.024% compared with Timolol 0.5% in lowering intraocular pressure over 24 hoursAm J Ophthalmol201616924925727457257
   PubMed Web of Science ®Google Scholar
• WeinrebRNLiebmannJMMartinKRKaufmanPLVittitowJLLatanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findingsJ Glaucoma201827171529194198
   PubMed Web of Science ®Google Scholar
• KawaseKVittitowJLWeinrebRNAraieMJUPITER Study GroupLong-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER StudyAdv Ther20163391612162727457469
   PubMed Web of Science ®Google Scholar
• CantisaniCAmbrifiMFrascaniFGlaucoma eye drops adverse skin reactionsRecent Pat Inflamm Allergy Drug Discov20148319219525487259
   PubMedGoogle Scholar
• Aguayo BonniardAYeungJYChanCCBirtCMOcular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK)Expert Opin Drug Metab Toxicol20161812791289
   Web of Science ®Google Scholar
• UusitaloHEgorovEKaarnirantaKAstakhovYRopoABenefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trialsClin Ophthalmol20161044545427041987
   PubMed Web of Science ®Google Scholar
• ThygesenJGlaucoma therapy: preservative-free for all?Clin Ophthalmol20181270771729713138
   PubMed Web of Science ®Google Scholar
• MedeirosFAMartinKRPeaceJScassellati SforzoliniBVittitowJLWeinrebRNComparison of Latanoprostene bunod 0.024% and Timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR studyAm J Ophthalmol201616825025927210275
   PubMed Web of Science ®Google Scholar
• QuigleyHABromanATThe number of people with glaucoma worldwide in 2010 and 2020Br J Ophthalmol200690326226716488940
   PubMed Web of Science ®Google Scholar
• Newman-CaseyPAShteinRMColemanALHerndonLLeePPWhy patients with glaucoma lose vision: the patient perspectiveJ Glaucoma2016257e668e67526317482
   PubMed Web of Science ®Google Scholar
• NelsonPAspinallPPapasouliotisOWortonBO’BrienCQuality of life in glaucoma and its relationship with visual functionJ Glaucoma200312213915012671469
   PubMed Web of Science ®Google Scholar
• GoldbergIClementCIChiangTHAssessing quality of life in patients with glaucoma using the Glaucoma Quality of Life-15 (GQL-15) questionnaireJ Glaucoma200918161219142128
   PubMed Web of Science ®Google Scholar
• LaceyJCateHBroadwayDCBarriers to adherence with glaucoma medications: a qualitative research studyEye200923492493218437182
   PubMed Web of Science ®Google Scholar
• StrykerJEBeckADPrimoSAAn exploratory study of factors influencing glaucoma treatment adherenceJ Glaucoma2010191667220075676
   PubMed Web of Science ®Google Scholar
• TsaiJCMcclureCARamosSESchlundtDGPichertJWCompliance barriers in glaucoma: a systematic classificationJ Glaucoma200312539339814520147
   PubMed Web of Science ®Google Scholar
• Newman-CaseyPARobinALBlachleyTThe most common barriers to glaucoma medication adherence: a cross-sectional surveyOphthalmology201512271308131625912144
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics. Xalatan 50 micrograms/ml Eye Drops Solution. Pfizer Limited Updated. Available from: https://www.medicines.org.uk/emc/product/1616/smpc
   Google Scholar
• HaverkampFWuenschSFuchsMStewartWCIntraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from adjunctive and monotherapy treatmentsEur J Ophthalmol200414540741515506603
   PubMed Web of Science ®Google Scholar
• ZimmermanTJStewartWCLatanoprost Axis Study GroupIntraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatmentsJ Ocul Pharmacol Ther200319540541514583133
   PubMed Web of Science ®Google Scholar
• FeldmanRMConjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertensionJ Ocul Pharmacol Ther2003191233512648301
   PubMed Web of Science ®Google Scholar
• DinslageSDiestelhorstMKühnerHKrieglsteinGKThe effect of latanoprost 0.005% on pupillary reaction of the human eyeOphthalmologe200097639640110916381
   PubMed Web of Science ®Google Scholar
• GelattKNMackayEOEffect of different dose schedules of latanoprost on intraocular pressure and pupil size in the glaucomatous BeagleVet Ophthalmol20014428328811906665
   PubMed Web of Science ®Google Scholar
• MarchiniGGhilottiGBonadimaniMBabighianSEffects of 0.005% latanoprost on ocular anterior structures and ciliary body thicknessJ Glaucoma200312429530012897573
   PubMed Web of Science ®Google Scholar
• ZarnowskiTKawaPJurkowska-DudzińskaJZagórskiZClinical evaluation of isopropyl unoprostone (Rescula), in the adjunctive treatment of primary open angle glaucomaKlin Oczna20011031131511605578
   PubMedGoogle Scholar
• Ba-AliSSanderBBrøndstedAELund-AndersenHEffect of topical anti-glaucoma medications on late pupillary light reflex, as evaluated by pupillometryFront Neurol201569325972838
   PubMed Web of Science ®Google Scholar
• FordBAGooiMCarlssonACrichtonACMorning dosing of once-daily glaucoma medication is more convenient and may lead to greater adherence than evening dosingJ Glaucoma20132211421946541
   PubMed Web of Science ®Google Scholar
• SleathBRobinALCovertDByrdJETudorGSvarstadBPatient-reported behavior and problems in using glaucoma medicationsOphthalmology2006113343143616458967
   PubMed Web of Science ®Google Scholar
• FriedmanDSHahnSRGelbLDoctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency StudyOphthalmology200811581320132718321582
   PubMed Web of Science ®Google Scholar